Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says

Executive Summary

“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.

You may also be interested in...



New US FDA Generics Director Praises Industry, Encourages Partnerships

Refuse-to-receive rates for ANDAs are down, suggesting sponsors better understand the standards for quality applications, Office of Generic Drugs Director Sally Choe says in first speech to industry.

Generic Industry Once Again Must Get To Know New US FDA Office Director

Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.

Will GDUFA III Curtail Priority Assessments?

US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel